Based on the PolyPeptide Group AG stock forecast from 0 analysts, the average analyst target price for PolyPeptide Group AG is not available over the next 12 months. PolyPeptide Group AG’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of PolyPeptide Group AG is Slightly Bearish, which is based on 4 positive signals and 5 negative signals. At the last closing, PolyPeptide Group AG’s stock price was CHF 28.75. PolyPeptide Group AG’s stock price has changed by +4.74% over the past week, +6.48% over the past month and +72.78% over the last year.
No recent analyst target price found for PolyPeptide Group AG
No recent average analyst rating found for PolyPeptide Group AG
Company Overview PolyPeptide Group AG
PolyPeptide Group AG operate as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of peptide-based therapies for metabolic disorders, including the GLP-1 receptor agonist drugs for the treatment of type 2 diabetes, obesity, and other co-morbidities, as well as oncology, hormonal disorders, neurology, ophthalmology, cardiovascular, and gastrointestinal applications. It also provides peptides for cosmetics; and individualized peptide therapeutics. The company was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V. Read Less
PolyPeptide Group AG operate as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for ph...Read More
Frequently Asked Questions About PolyPeptide Group AG (PPGN:SW) Stock
Stock Target Advisor's fundamental analysis for PolyPeptide Group AG's stock is Slightly Bearish.
Unfortunately we do not have enough data on PPGN:SW's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on PPGN:SW's stock to indicate what its average analyst target is.
PPGN:SW stock's Price/Earning ratio is 106.52.
Our analysis grades PPGN:SW stock's Price / Earning ratio at D+. This means that PPGN:SW stock's Price/Earning ratio is above 32.99999999999999% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the SW exchange.
Based on this PPGN:SW may be fairly valued for its sector
The last closing price of PPGN:SW's stock was CHF 28.75.
The most recent market capitalization for PPGN:SW is CHF 0.92B.
Unfortunately we do not have enough analyst data on PPGN:SW's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains PolyPeptide Group AG's stock.
As per our most recent records PolyPeptide Group AG has 1,277 Employees.
PolyPeptide Group AG's registered address is Neuhofstrasse 24, Baar, Switzerland, 6340.
You can get more information about it from PolyPeptide Group AG's website at https://www.polypeptide.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Underpriced on cashflow basis
The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About PolyPeptide Group AG (PPGN:SW) Stock
Stock Target Advisor's fundamental analysis for PolyPeptide Group AG's stock is Slightly Bearish.
Unfortunately we do not have enough data on PPGN:SW's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on PPGN:SW's stock to indicate what its average analyst target is.
PPGN:SW stock's Price/Earning ratio is 106.52.
Our analysis grades PPGN:SW stock's Price / Earning ratio at D+. This means that PPGN:SW stock's Price/Earning ratio is above 32.99999999999999% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the SW exchange.
Based on this PPGN:SW may be fairly valued for its sector
The last closing price of PPGN:SW's stock was CHF 28.75.
The most recent market capitalization for PPGN:SW is CHF 0.92B.
Unfortunately we do not have enough analyst data on PPGN:SW's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains PolyPeptide Group AG's stock.
As per our most recent records PolyPeptide Group AG has 1,277 Employees.
PolyPeptide Group AG's registered address is Neuhofstrasse 24, Baar, Switzerland, 6340.
You can get more information about it from PolyPeptide Group AG's website at https://www.polypeptide.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PPGN:SW !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
